Global DTaP Vaccine Market Overview:
DTaP (Diphtheria-Tetanus-acellular Pertussis) vaccine is a combination immunizing agent given by injection to protect against infections caused by diphtheria, tetanus (lockjaw), and pertussis (whooping cough). Diphtheria and tetanus (DT) vaccine is given to children and combined tetanus, diphtheria and acellular pertussis (Tdap) vaccine is given to adolescents and adults. As per sources, in 2017, DTaP vaccine sales value in china was ~27 Million USD. In 2018, ~151 000 cases of pertussis were registered globally. In addition, 86% of the global target population received the recommended three doses of DTP-containing vaccine during infancy in 2018. The rising government and non-government initiatives for vaccine development are expected to offer lucrative opportunities for market growth in the estimated forecast period.
- Introduction Of Combination Vaccines
- Enhancement Of Vaccine Development Technology
- Increasing Incidences Of Diphtheria, Tetanus And Pertussis
- Reactions Such As Seizure Or High Fever in Children
- Favorable R&D Scenario
- Demand For D&T Containing Vaccines
- Growing Efforts By Global Organizations To Promote Immunization Programs
- Strict Regulation & Longer Timeline Required To Produce Vaccines
The providers in the global DTaP vaccine market continue to focus on innovation and updation in their products. Such developments coupled with competitive pricing are likely to assist in increasing market share over the forecast period. The key players are investing heavily in research & development to enhance their product effectiveness on treating diphtheria, tetanus & pertussis diseases to maintain their market presence in altering consumer buying preferences.
Some of the key players profiled in the report are GlaxoSmithKline plc (United Kingdom), Sanofi (France), Novartis International AG (Switzerland), Merck (Germany), Pfizer Inc. (United States), Astellas Pharma Inc. (United States), Emergent BioSolutions Inc. (United States), AstraZeneca plc (United Kingdom), Serum Institute Of India (India) and Grifols, S.A.(Spain). Considering Market by Product Type, the sub-segment i.e. Generic Drug will boost the DTaP Vaccine market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the DTaP Vaccine market.
In September 2020, Sanofi’s part Sanofi Pasteur India launched Tetraxim (DTaP-IPV) vaccine. This vaccine is indicated for preschoolers and provides protection against four major diseases that includes Diphtheria, Pertussis, Tetanus and Polio.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global DTaP Vaccine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in DTaP Vaccine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, DTaP Vaccine Manufacturer, Raw Material Suppliers, Traders and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.